Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR25043631

—

5a903d9e-2089-5bbb-af91-82a86cf93fd2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.570
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
  • MYOGENESIS+0.560
  • IL6_JAK_STAT3_SIGNALING+0.500
  • COAGULATION+0.460
  • TNFA_SIGNALING_VIA_NFKB+0.440
  • INFLAMMATORY_RESPONSE+0.430
  • COMPLEMENT+0.390
  • IL2_STAT5_SIGNALING+0.370
  • ALLOGRAFT_REJECTION+0.350

Top 10 suppressed

  • E2F_TARGETS-0.660
  • G2M_CHECKPOINT-0.640
  • MYC_TARGETS_V1-0.580
  • MYC_TARGETS_V2-0.470
  • MITOTIC_SPINDLE-0.320
  • MTORC1_SIGNALING-0.280
  • PROTEIN_SECRETION-0.260
  • DNA_REPAIR-0.250
  • SPERMATOGENESIS-0.190
  • ESTROGEN_RESPONSE_LATE-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1d3119bbd-8c3d-4f95-863c-a04ae8b18eb9
colon-landscapes@1
——0.921
2TCGA-XF-AAN8-01A-11R-A42T-07
bladder-landscape@3
——0.916
3C3L-02164
lung-landscapes@6
—cohortMD20.908
4TCGA-A2-A0EP-01A-52R-A22U-07
breast-umap@18
—A0.908
545b4921e-fce7-41f8-bb63-ed98343ceec8
colon-landscapes@1
——0.907
6TCGA-XF-A9SL-01A-11R-A39I-07
bladder-landscape@3
——0.903
7TCGA-BH-A0DI-01A-21R-A12P-07
breast-umap@18
—A0.902
8TCGA-K4-A83P-01A-11R-A352-07
bladder-landscape@3
——0.901
9TCGA-CN-4728-01A-01R-1436-07
head-neck@1
——0.900
10TCGA-A2-A0EN-01A-13R-A084-07
breast-umap@18
—A0.899

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.570Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.570Inavolisib— uncovered
MYOGENESIS0.560Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
COAGULATION0.460Binimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.440Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.430Idelalisib— uncovered
COMPLEMENT0.390Inavolisib— uncovered
IL2_STAT5_SIGNALING0.370Idelalisib— uncovered
ALLOGRAFT_REJECTION0.350Idelalisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.240Idelalisib— uncovered
KRAS_SIGNALING_UP0.240Inavolisib— uncovered
APICAL_JUNCTION0.230Inavolisib— uncovered
APOPTOSIS0.230Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.230Inavolisib— uncovered
NOTCH_SIGNALING0.210Inavolisib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
KRAS_SIGNALING_DN0.170Remibrutinib— uncovered